Charles River Laboratories International, Inc. has made several appointments. Brian Bathgate, Ph.D. has been named corporate senior vice president and president, European Preclinical Services. Jorg Geller, D.V.M., Ph.D. has been named corporate senior vice president, Japanese Operations and Global Large Research Model and Avian Operations. Christopher Perkin has been named corporate senior vice president and president, Canadian Preclinical Services.

Dr. Bathgate joined CRL in December 2004, following its merger with Inveresk. Since joining the organization, he has assumed responsibility for its global biopharmaceutical business, as well as drug discovery and development services in Ireland. In addition, Dr. Bathgate is also responsible for the Phase I clinical business in Edinburgh.

Dr. Geller joined Charles River Germany in 1986, overseeing its research model production operations. In 1997, he became responsible for Avian operations on a global basis. In 2004, Dr. Geller was given responsibility for global large research model operations. In his expanded role, Dr. Geller will also assume responsibility for Charles River Japan.

Mr. Perkin also joined Charles River in 2004, after the Inveresk merger, and was named corporate vice president and president, Canadian Preclinical Services. He manages Charles River’s largest facility, which will soon be expanded. In addition, he oversees the preclinical services operations in Pennsylvania. Under his direction, Charles River also established preclinical operations in China this year.

“The managerial expertise and impressive track records of Brian, Jorg and Chris have played an integral role in our company’s growth and success. Their ability to anticipate and exceed customer expectations enables us to remain steadfast in our commitment to providing superior products and services,” said James C. Foster, chairman, president and chief executive officer of CRL.